^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Colorectal Cancer

Related cancers:
10h
Pharmacologic Ascorbate Radiosensitizes Pancreatic Cancer but Radioprotects Normal Tissue: The Role of Oxidative Stress-Induced Lipid Peroxidation. (PubMed, Antioxidants (Basel))
To determine the mechanism, pancreatic cancer cells were treated with selenomethionine or RSL3, an inhibitor of glutathione peroxidase 4 (GPx4). RSL3 treatment inhibited GPx4 activity and increased lipid peroxidation. Differences in oxidative stress may play a role in radioprotecting normal cells while radiosensitizing pancreatic cancer cells when treated with P-AscH-.
Journal
|
GPX4 (Glutathione Peroxidase 4)
|
RSL3 • selenomethionine (SLM)
10h
Norcantharidin Sensitizes Colorectal Cancer Cells to Radiotherapy via Reactive Oxygen Species-DRP1-Mediated Mitochondrial Damage. (PubMed, Antioxidants (Basel))
Our findings provide evidence for the potential therapeutic use of NCTD and IR against CRC. Moreover, this study elucidates whether NCTD can overcome CRC radiation tolerance and provides insights into the underlying mechanisms.
Journal
|
CHEK2 (Checkpoint kinase 2) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
10h
Calocedrus formosana Essential Oils Induce ROS-Mediated Autophagy and Apoptosis by Targeting SIRT1 in Colon Cancer Cells. (PubMed, Antioxidants (Basel))
The induction of apoptosis and autophagy by CF-EOs suggests that they may have potential as a promising new approach for treating cancer. Collectively, our results suggest that essential oils isolated from Calocedrus formosana act as a promising anticancer agent against colon cancer cells by targeting SIRT1 to induce ROS-mediated autophagy and apoptosis.
Journal • PARP Biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • ATG5 (Autophagy Related 5) • SIRT1 (Sirtuin 1) • ATG7 (Autophagy Related 7)
|
TP53 mutation • TP53 wild-type
10h
Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid Tumors. (PubMed, Cancers (Basel))
With advancements in detection technologies, several approaches to the treatment of BRAF-mutant cancers have been taken. In this review, we retrace the milestones that led to the clinical development of targeted therapies currently available for these tumors.
Review • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF mutation • BRAF V600
10h
Determination of the Prevalence of Microsatellite Instability, BRAF and KRAS/NRAS Mutation Status in Patients with Colorectal Cancer in Slovakia. (PubMed, Cancers (Basel))
We identified 4 MSI-high samples, 39 KRAS/NRAS mutations, and 5 BRAF p.V600E mutations, with one case of coexistence of all three markers in a single tumor sample. We also evaluated possible relationships between biomarkers, their coexistence, and the age and sex of the studied population.
Journal • Microsatellite instability • MSi-H Biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
|
BRAF V600E • KRAS mutation • MSI-H/dMMR • BRAF mutation • NRAS mutation • BRAF V600
10h
Characteristics of Cancer Stem Cells and Their Potential Role in Endometrial Cancer. (PubMed, Cancers (Basel))
However, there is much left to discover. Therefore, more studies are needed to fully uncover their functional mechanisms in order to prevent the development and recurrence of cancer, as well as to enhance treatment effectiveness.
Review • Journal • Cancer stem • IO biomarker
|
NOTCH1 (Notch 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CD24 (CD24 Molecule) • CD9 (CD9 Molecule) • CD40 (CD40 Molecule)
10h
Concurrent KRAS p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case report. (PubMed, Diagn Pathol)
The identification of both a KRAS p.G12C mutation and an ANK3::RET fusion in the same CRC patient adds a new layer to the oncogenic landscape and treatment considerations for CRC. It highlights the intricate decision-making required in the era of precision medicine, where targeted therapies must be carefully chosen and potentially combined to combat complex genetic profiles. The case emphasizes the urgency of investigating the clinical effects of concurrent or sequential use of KRAS p.G12C and RET inhibitors to inform future therapeutic guidelines and improve patient outcomes in similar cases.
Journal • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • RET (Ret Proto-Oncogene) • ANK3 (Ankyrin 3)
|
KRAS mutation • KRAS G12C • RET fusion • RET mutation • KRAS G12
10h
Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD. (PubMed, J Transl Med)
Together, our findings establish the immunogenicity and therapeutic potential of mutant MUC family-derived neoantigens. Through combining the tools of TSNAdb and DAI, a group of novel MUCmut neoantigens were identified as potential targets for immunotherapy.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • MUC16 (Mucin 16, Cell Surface Associated) • MUC4 (Mucin 4, Cell Surface Associated) • MUC13 (Mucin 13) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming) • MUC2 (Mucin 2) • MUC20 (Mucin 20 Cell Surface Associated) • MUC17 (Mucin 17) • MUC6 (Mucin 6)
|
TMB-H • MUC16 mutation • MUC5B mutation
10h
HER2-Positive Metastatic Colorectal Cancer. (PubMed, Curr Treat Options Oncol)
At present, standard of care first-line treatment for those with HER2-positive mCRC remains chemotherapy in combination with epidermal growth factor receptor (EGFR) inhibitors or bevacizumab, depending on RAS/BRAF mutational status and tumor sidedness...While the choice of anti-HER2 therapy is empiric given lack of head-to-head comparisons, the combination of trastuzumab plus tucatinib has received FDA accelerated approval for use in this setting and is generally the authors' preference. Trastuzumab plus lapatinib, trastuzumab plus pertuzumab, and trastuzumab deruxtecan (T-DXd) also have evidence of efficacy in this setting...These include the optimal sequence of anti-HER2 therapies with chemotherapy and anti-EGFR therapies, the optimal combination partners for anti-HER2 therapies, and the incorporation of predictive biomarkers to guide use of anti-HER2 therapies. Results of ongoing studies may thus alter the treatment paradigm above in the coming years.
Review • Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
|
HER-2 positive • HER-2 overexpression • BRAF mutation • HER-2 amplification • HER-2 mutation • BRAF wild-type • RAS mutation • EGFR positive
|
Avastin (bevacizumab) • lapatinib • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib)
11h
Association between microsatellite status and characteristics and outcomes of early-onset compared to late-onset rectal cancer. (PubMed, Int J Colorectal Dis)
In both age groups, MSI-H rectal cancers were more often mucinous and poorly differentiated carcinomas and had pT3-4 stage more often than MSS cancers. MSI-H rectal cancers tend to present less often with distant metastases and nodal involvement than MSS cancers only in early-onset, but not in late-onset rectal cancers. The association between MSI status and survival was not notable in this study, whether in the early-onset or late-onset groups.
Journal
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
11h
YWHAG promotes colorectal cancer progression by regulating the CTTN-Wnt/β-catenin signaling axis. (PubMed, Med Oncol)
CTTN was identified as a YWHAG-associated protein, and mediated its tumor-promoting functions by activating the Wnt/β-catenin signaling in CRC cells. In summary, our data indicate that YWHAG facilitates the proliferation, migration, and invasion of CRC cells by modulating the CTTN-Wnt/β-catenin signaling pathway, which offers a novel perspective for the treatment of CRC.
Journal
|
CTTN (Cortactin) • YWHAG (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Gamma)
15h
Real-time Artificial Intelligence-based Endocytoscopic Diagnosis of Colorectal Neoplasms (clinicaltrials.gov)
P=N/A, N=350, Not yet recruiting, The First Hospital of Jilin University
New trial
16h
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer (clinicaltrials.gov)
P2, N=50, Not yet recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2027 --> Apr 2028 | Initiation date: Jan 2024 --> Jan 2025 | Trial primary completion date: Apr 2025 --> Apr 2026
Trial completion date • Trial initiation date • Trial primary completion date • Tumor mutational burden
|
MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
MSI-H/dMMR
|
Libtayo (cemiplimab-rwlc)
16h
BMI and Lymph Node Count in Colorectal Cancer (clinicaltrials.gov)
P=N/A, N=1192, Completed, Klinikum Floridsdorf
New trial
16h
ERAS in Colorectal Surgery: Benefits of Late Adoption (clinicaltrials.gov)
P=N/A, N=456, Completed, University Hospital, Basel, Switzerland | Not yet recruiting --> Completed
Trial completion • Surgery
18h
New trial
18h
Introducing a Plant-Based Diet for Patients With Colorectal Diseases (clinicaltrials.gov)
P=N/A, N=60, Not yet recruiting, Stanford University | Trial completion date: Mar 2023 --> Dec 2025 | Trial primary completion date: Feb 2023 --> Dec 2025
Trial completion date • Trial primary completion date
20h
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer. (PubMed, Mol Cancer)
This study provides new data on the feasibility, efficacy, and immune context of tumors that may help identifying advanced CRC patients most likely to respond to immuno-radiotherapy.
P2 data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCL19 (C-C Motif Chemokine Ligand 19) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • IRF1 (Interferon Regulatory Factor 1)
|
PD-L1 expression • IRF1 expression
|
Tecentriq (atezolizumab)
20h
Elevated postoperative carcinoembryonic antigen guides adjuvant chemotherapy for stage II colon cancer: a multicentre cohort retrospective study. (PubMed, Sci Rep)
Patients with elevated postoperative CEA levels have a significantly increased risk of recurrence. They should be included as high-risk factors to guide adjuvant chemotherapy for stage II colon cancer.
Retrospective data • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
20h
Association of Preoperative and Postoperative Plasma Syndecan-1 and Colorectal Cancer Outcome. (PubMed, Anticancer Res)
Dynamic change in serum SDC1 levels serves as a prognostic biomarker for stage II and III colorectal cancer.
Journal
|
SDC1 (Syndecan 1)
|
SDC1 expression
20h
CD8-positive T Cell Infiltration With Human Leukocyte Antigen Class 1 Expression Predicts Patients With Stage IV Colorectal Cancer Survival. (PubMed, Anticancer Res)
The combination of CD8+ T cell infiltration and HLA1 expression is crucial for cancer immune microenvironment evaluation in CRCs.
Journal • Metastases
|
CD8 (cluster of differentiation 8)
|
CD8 expression • CD8 positive • CD8-H
22h
Transcriptomes of cervical cancer provide novel insights into dysregulated pathways, potential therapeutic targets, and repurposed drugs. (PubMed, Cancer Treat Res Commun)
Furthermore, it was observed that AKT1, MAPK1, and MAPK3 ranked the highest among the regulatory genes that hold promise as therapeutic targets in the context of cervical cancer. Additional research, both in vitro and in vivo, is required to validate and establish the therapeutic potential of these crucial genes in the context of cervical cancer.
Journal
|
GNAQ (G Protein Subunit Alpha Q) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • KLF4 (Kruppel-like factor 4) • MAPK1 (Mitogen-activated protein kinase 1) • FOXM1 (Forkhead Box M1) • E2F1 (E2F transcription factor 1) • MAPK3 (Mitogen-Activated Protein Kinase 3) • PPM1A (Protein Phosphatase Mg2+/Mn2+ Dependent 1A) • PPP2CA (Protein Phosphatase 2 Catalytic Subunit Alpha 2)
22h
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability. (PubMed, Eur J Cancer)
In the absence of randomized trials, our study highlights the superior efficacy of ICI compared with standard-of-care therapy in patients with unresectable or metastatic dMMR/MSI-H non-colorectal digestive cancer, regardless of tumor type, with acceptable toxicity.
Clinical • Journal • Checkpoint inhibition • Microsatellite instability • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
22h
Prognostic usefulness of the C-reactive protein-albumin-lymphocyte (CALLY) index as a novel biomarker in patients undergoing colorectal cancer surgery. (PubMed, Asian J Surg)
The CALLY index may be an independent prognostic biomarker for long-term outcomes in patients with colorectal cancer.
Journal • Surgery
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • CRP (C-reactive protein)
|
Albumin-L
22h
Netrin-1 Role in Nociceptive Neuron Sprouting through Activation of DCC Signaling in a Rat Model of Bone Cancer Pain. (PubMed, J Integr Neurosci)
Netrin-1 may contribute to the activation of the BCP by inducing nociceptive nerve innervation and improving pain behaviors.
Preclinical • Journal
|
RAC1 (Rac Family Small GTPase 1) • CDC42 (Cell Division Cycle 42) • NTN1 (Netrin 1)
22h
Phosphoglycerate Kinase 1: An Effective Therapeutic Target in Cancer. (PubMed, Front Biosci (Landmark Ed))
This review provides a comprehensive summary of PGK1's expression pattern, structural features, functional properties, involvement in PTMs, and interaction with tumors. Additionally highlighted are the prospects for developing and applying related inhibitors that confirm the indispensable value of PGK1 in tumor progression.
Review • Journal
|
PGK1 (Phosphoglycerate Kinase 1)
1d
Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT:AP-1 signaling. (PubMed, Sci Adv)
Analysis of primary human colon cancer specimens reveals positive correlations between DNMTi-, innate immune response-, and calcium signaling-associated transcription profiles. Collectively, we show that compensatory EZH2 activity limits DNMTi efficacy in colon cancer and link NFAT:AP-1 signaling to epigenetic therapy-induced viral mimicry.
Journal
|
NFATC1 (Nuclear Factor Of Activated T Cells 1)
1d
Folate induces stemness and increases oxygen consumption under glucose deprivation by notch-1 pathway activation in colorectal cancer cell. (PubMed, Mol Cell Biochem)
These results suggest that FA protects against glucose deprivation. These effects were associated with AMPK activation, a critical metabolic mediator in nutrient consumption and availability that activates the Notch-1 pathway.
Journal
|
NOTCH1 (Notch 1)
|
NOTCH1 expression
1d
The Impact of Atmospheric Cadmium Exposure on Colon Cancer and the Invasiveness of Intestinal Stents in the Cancerous Colon. (PubMed, Toxics)
Cd partially fosters CC tumorigenesis via the ROS-mediated Wnt/β-catenin signaling pathway. The effect of Cd on the invasive effect of intestinal stents in the cancerous colon is not significant.
Journal
|
CAT (Catalase) • SOD1 (Superoxide Dismutase 1) • SOD2 (Superoxide Dismutase 2)
1d
Unraveling the Multifaceted Role of the miR-17-92 Cluster in Colorectal Cancer: From Mechanisms to Biomarker Potential. (PubMed, Curr Issues Mol Biol)
Ultimately, miR-17-92 holds promise as a biomarker for prognosis and therapy response, as well as a potential target for cancer prevention and therapeutic interventions. In essence, this review underscores the multifaceted nature of miR-17-92 in CRC research, offering promising avenues for enhancing the management of CRC patients.
Review • Journal
|
MIR17HG (MiR-17-92a-1 Cluster Host Gene) • MIR17 (MicroRNA 17)
1d
The Humanization and Maturation of an Anti-PrPc Antibody. (PubMed, Bioengineering (Basel))
Used for Western blotting and immunohistochemistry, the humanized antibody with the highest affinity is superior to the two most frequently used commercial antibodies (8H4 and 3F4). The two new antibodies have the potential to be developed as useful reagents for PrPc detection and even therapeutic antibodies targeting PrPc-positive cancers.
Journal
|
PRNP (Prion Protein)
1d
Systematic scoping review: Use of the faecal immunochemical test residual buffer to enhance colorectal cancer screening. (PubMed, Aliment Pharmacol Ther)
This scoping review summarises the framework and progress of research on stability of biomarkers in FIT residual buffer and their associations with colorectal neoplasia to guide opportunities for further confirmatory studies to enhance colorectal cancer screening.
Review • Journal
|
MIR27A (MicroRNA 27a) • MIR16 (MicroRNA 16) • MIR223 (MicroRNA 223) • MIR148A (MicroRNA 148a) • MIRLET7B (MicroRNA Let-7b)
1d
Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. (PubMed, Gut Microbes)
Furthermore, mechanistic investigation demonstrated that F. nucleatum could regulate the Hippo pathway and promote the expression of BCL2, thereby inhibiting the Caspase-3/GSDME pyroptosis-related pathway induced by chemotherapy drugs and mediating CRC cell chemoresistance. Taken together, these results validated the significant roles of F. nucleatum in CRC chemoresistance, which provided an innovative theoretical basis for the clinical diagnosis and therapy of CRC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • GSDME (Gasdermin E)
|
BCL2 expression
1d
CXCR4-Targeted Macrophage-Derived Biomimetic Hybrid Vesicle Nanoplatform for Enhanced Cancer Therapy through Codelivery of Manganese and Doxorubicin. (PubMed, ACS Appl Mater Interfaces)
Local administration of hybrid nanovesicles also induced an abscessive effect in a bilateral 4T1 tumor model. This study demonstrates a promising biomimetic manganese/doxorubicin-based hybrid nanovesicle platform for effective cancer immunotherapy tailored to the tumor microenvironment, which may offer an innovative approach to combinatorial immunotherapy.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • STING (stimulator of interferon response cGAMP interactor 1)
|
CXCR4 expression
|
doxorubicin hydrochloride
1d
Unraveling the causal role of immune cells in gastrointestinal tract cancers: insights from a Mendelian randomization study. (PubMed, Front Immunol)
These traits include "CCR2 on CD14- CD16+ monocyte," "CD19 on IgD+ CD38-," "CD19 on IgD+ CD38- naive," "CD25hi CD45RA+ CD4 not Treg AC," "CD27 on unsw mem," "CD28 on CD39+ activated Treg," and "CD45 on CD4+." This study elucidates a causal link between immune cells and gastrointestinal tract cancers at various sites through genetic investigation. The findings of this research open up new perspectives and resources for exploring tumor prevention strategies and immunotherapeutic targets.
Journal • Immune cell
|
CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • CCR2 (C-C Motif Chemokine Receptor 2) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
1d
Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes. (PubMed, Front Immunol)
Our findings demonstrate that IL-38 expression in colorectal regional nodes from CRC patients is inversely correlated with PD-1/PD-L1 but positively correlated with infiltrating CD4+ or CD8+ lymphocytes. The combined assessment of IL-38 and PD-1 expression in colorectal regional nodes emerges as a promising biomarker for predicting the prognosis of CRC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
PD-1 expression • CD8 expression • CD4 expression • PD-1 underexpression
1d
Novel biomarkers of inflammation-associated immunity in cervical cancer. (PubMed, Front Oncol)
In addition, we assessed their diagnostic value and further analyzed the association of immune cells with them. Five inflammation- and immune-related genes were identified, aiming to provide new directions for early diagnosis and mid to late-stage treatment of CC from multiple perspectives.
Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
1d
Habitat-based radiomics analysis for evaluating immediate response in colorectal cancer lung metastases treated by radiofrequency ablation. (PubMed, Cancer Imaging)
The habitat-based radiomics signature can offer precise predictions and valuable assistance to physicians in developing personalized treatment strategies.
Journal
|
CA 19-9 (Cancer antigen 19-9)
1d
Tumoricidal properties of thymoquinone on human colorectal adenocarcinoma cells via the modulation of autophagy. (PubMed, BMC Complement Med Ther)
Here, we monitored the effects of Thymoquinone (TQ) on autophagy via mitochondrial function after modulation of the Wnt/β-catenin signaling pathway.Human colorectal adenocarcinoma HT-29 cells were treated with TQ (60 µM) and 15 µM Wnt3a inhibitor (LGK974) for 48 h...TQ can increase intracellular accumulation of Rhodamine 123, indicating the inhibition of efflux mechanisms in cancer cells. Along with these changes, the migration of cells was also reduced (p < 0.05).TQ is a potential phytocompound to alter the dynamic growth of human colorectal HT-29 cells via the modulation of autophagy, and mitophagy-related mechanisms.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • AXIN1 (Axin 1) • BECN1 (Beclin 1) • CDH5 (Cadherin 5) • PINK1 (PTEN Induced Kinase 1)
|
MYC expression • CDH1 expression
|
WNT974
1d
Procalcitonin and C-reactive protein as early markers of anastomotic leakage in intestinal resections for advanced ovarian cancer (EDMOCS). (PubMed, Acta Obstet Gynecol Scand)
Procalcitonin and C-reactive protein are potential biomarkers for early detection of anastomotic leakage after ovarian cancer surgery with bowel resection. Further prospective studies with a larger sample size are needed to confirm these findings.
Journal • Metastases
|
CRP (C-reactive protein)
1d
The C-type lectin DCIR contributes to the immune response and pathogenesis of colorectal cancer. (PubMed, Sci Rep)
This phenotype is accompanied by an altered phenotype of tumor-associated macrophages (TAMs) and a reduction in the percentage of activated effector CD4+ and CD8+ T cells in CRC tumors of DCIR1-deficient mice. Overall, our results show that DCIR promotes antitumor immunity in CRC, making it an attractive target for the future development of immunotherapies to fight the second deadliest cancer in the world.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
1d
Identification of unique rectal cancer-specific subtypes. (PubMed, Br J Cancer)
We conclude that RSS subtyping allows for more accurate prognosis predictions in rectal cancers than CMS subtyping and provides new insight into targetable disease pathways within these subtypes.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1)
|
MYC expression